24/7 Market News Snapshot 20 June, 2025 – Firefly Neuroscience, Inc. Common Stock (NASDAQ:AIFF)

June 20, 2025

DENVER, Colo., 20 June, 2025 (www.247marketnews.com) – (NASDAQ:AIFF) are discussed in this article.
Firefly Neuroscience, Inc. is experiencing a significant surge in market interest, with shares soaring to $3.659 in pre-market trading, representing an impressive 21.97% increase from the previous day’s close of $3.00. This uptick is supported by a noteworthy trading volume of 9.42 million shares, reflecting strong investor enthusiasm and optimism about the company’s future prospects.

The bullish performance coincides with the release of pivotal research advancements that position Firefly at the forefront of Alzheimer’s diagnostics. The company has introduced a promising dual diagnostic approach that effectively differentiates between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia. According to findings from a recent study, the integration of electroencephalography (EEG) with volumetric magnetic resonance imaging (vMRI) enhances diagnostic accuracy to approximately 87%.

Significantly, specific EEG measures, such as reaction time and P300b amplitude, have been identified as reliable indicators of cognitive impairment, achieving predictive accuracies of around 80% when employed independently. The combination of these methods, particularly through analyzing the left temporal lobe, underscores the potential for improved early detection of cognitive decline, which is essential for timely intervention.

Gil Issachar, Firefly’s Chief Technology Officer, highlighted the strategic benefits gained from the recent acquisition of Evoke Neuroscience, facilitating access to an extensive database of over 180,000 EEG assessment records. This collaboration promises to amplify the company’s early screening capabilities. CEO Greg Lipschitz also noted the powerful synergy created by integrating the FDA-cleared Brain Network Analytics (BNA™) technology with vMRI, positioning Firefly to revolutionize diagnostic practices and enhance patient outcomes in the realm of neurological disorders.

Related news for (AIFF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.